4G World, Chicago, IL - October 18, 2010- ZTE Corporation, a leading global provider of telecommunications equipment and network solutions, today launched the ZXMBW R9110, the world's first WiMAX/TD-LTE dual-mode Remote Radio Unit (RRU) at 4G World 2010. As the industry leader in Long Term Evolution in Time Division Duplex (LTE TDD) technology, ZTE was the first vendor to offer a smooth evolution from TD-SCDMA to TD-LTE with the ZXTR R8928 TD-SCDMA/LTE dual-mode Remote Radio Unit announced earlier this year. As anticipation for widespread commercial adoption of LTE in the North American market grows, the R9110 will respond to the evolving market needs as the latest addition to ZTE's full range of WiMAX/TD-LTE dual-mode base station offerings.
Supporting 2.3G/2.5GHz and 3.5GHz spectrum band, the R9110 has a unique 4T8R design and advanced antenna technologies such as multiple-input and multiple-output (MIMO) and beamforming (BF), providing operators with a successful transition strategy that can suit the market where various systems currently co-exist.
"Without a doubt, it's an exciting time in the U.S. telecom market. Many operators are embracing LTE and several have announced plans to launch commercial deployments through 2011," said Songpu Zhao, vice president, ZTE. "Operators are facing the challenge of how to leverage their existing technology investments while remaining competitive and ZTE is addressing this market need with the R9110. In addition to improving the speed of network deployments and significantly reducing the network total cost of ownership, it provides operators with a smooth migration path towards 4G."
ZTE Corporation is a leading supplier in both the TDD and LTE markets. ZTE has worked on more than 20 LTE projects in high-end markets including Spain, the United States, and Hong Kong, working with established operators such as Telenor, CSL (under Telstra Group), Etisalat, SingTel, Commnet Wireless/NTUA, and China Mobile. ZTE has to date rolled-out seven LTE commercial networks and over 50 LTE trials distributed in Europe, North America, the Middle East and Asia Pacific areas.
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}